Who Are the Core Customers in Veracyte Company's Target Market?

Endocrinologists ordering Afirma for thyroid nodules, urologists using Decipher for prostate risk stratification, and pulmonologists ordering Percepta for lung nodule evaluation are the core buyers; these physician specialists drive test volume and clinical guideline adoption.

Large integrated delivery networks, hospital systems, and commercial payors prioritize cost-saving diagnostic pathways and reimbursement policies – critical to scaling Veracyte target customers across clinics and hospitals.

Veracyte serves a mixed customer base: mainly B2B clinical buyers (specialist physicians, pathology labs, health systems) plus institutional payors and biopharma partners for R&D and trials; primary care physicians mainly act as referrers.

The thyroid market is largest by test volume: about 550,000 fine-needle aspiration biopsies performed annually in the U.S., and Afirma targets indeterminate nodules within that pool – while Decipher is standard-of-care in prostate risk stratification, driving high per-test revenue and uptake.

The US accounts for approximately 90 percent of diagnostic service revenue as of Q1 2026, fueled by referrals from oncologists, endocrinologists, pulmonologists, and primary care physicians who refer to Veracyte testing; urology and prostate care lead. Which doctors use Veracyte tests: specialists in oncology and endocrinology drive volume.

Veracyte is expanding in Europe and Asia via decentralized in vitro diagnostic deployments using the nCounter Analysis System, letting hospitals run tests locally and reducing shipping delays. Demand is also surging in the biopharmaceutical sector for genomic profiling in clinical trials and targeted-therapy development.

Veracyte appears strongest in reach and revenue mix in the US diagnostic lab channel and among physician specialists who use Veracyte molecular tests; the Decipher Prostate test's inclusion in NCCN guidelines has amplified uptake in urology and oncology practices.

Fastest growth is in urology (Decipher Prostate) and international in-vitro deployments in Europe/Asia; biopharma demand for genomic profiling rose in 2025 as more trials required molecular selection. For competitive context, see Competitive Landscape of Veracyte Company.

Veracyte broadens its Veracyte target customers by adding new genomic assays (notably the 2025 Minimal Residual Disease MRD oncology offering), moving from a single-product model to multi-indication platform sales that attract oncologists, endocrinologists, pulmonologists, and pathology labs; this attracts hospitals and clinics that use Veracyte and medical laboratories partnering with Veracyte.

Retention rises because Veracyte embeds tests into standard clinical workflows and billing pathways, securing reimbursement and making replacement costly for competitors; long-term contracts with health systems and strong payer coverage reduce churn among the Veracyte core customers and healthcare providers using Veracyte genomic tests.

Repeat demand comes from longitudinal uses (MRD monitoring) and reflex testing (Afirma thyroid follow-ups), driving recurring volumes from primary care physicians referring to Veracyte and physician specialists who use Veracyte molecular tests; tissue pathology labs using Veracyte assays and pulmonary specialists ordering Percepta contribute steady reorder rates.

The key lever is platform and margin scale: centralized lab capacity lets Veracyte absorb rising volumes of high-margin genomic tests, supporting projected 2026 revenue growth of 15 to 18 percent; the balance sheet at year-end 2025 held approximately 250 million USD in cash with minimal debt, enabling commercial expansion and sustained penetration into hospitals and clinics that use Veracyte.